Tarapchak brings more than 30 years of accounting and finance expertise to the role CHICAGO, April 14, 2025 (GLOBE NEWSWIRE) -- Verano Holdings Corp. (Cboe CA: VRNO) (OTCQX: VRNOF) (“Verano” or the “Company”), a leading multi-state cannabis company, today announced the promotion and appointment of Richard Tarapchak as the Company’s Chief Financial Officer (“CFO”), effective as of April 11, 2025. Tarapchak succeeds Brett Summerer, former Chief Financial Officer, who is departing the Company following his mut ...

Core Viewpoint - The implementation of tariffs is expected to create a ripple effect throughout the cannabis industry, impacting production costs, market prices, and the trading of marijuana stocks [1][2]. Industry Impact - Increased tariffs will likely raise import costs for essential materials in cannabis production, such as hydroponic systems and lighting equipment, leading to higher operational costs for cannabis farmers [1][2]. - As operational costs rise, cannabis operators may need to increase prices for their products, which could negatively affect top marijuana stocks in the short term [2]. Investment Perspective - Despite the current downturn in the cannabis sector, there are opportunities to find top marijuana stocks at lower prices, with investors speculating on a potential future turnaround [3]. - Investors are looking for signs of a stronger industry and success in the long term, indicating a hopeful outlook among cannabis stock shareholders [3]. Companies to Watch - **Green Thumb Industries Inc. (OTC:GTBIF)**: Engages in the manufacturing, distribution, marketing, and sale of cannabis products for medical and adult use in the U.S., operating through Retail and Consumer Packaged Goods segments [4][8]. - **Greenlane Holdings, Inc. (NASDAQ:GNLN)**: Focuses on the development and distribution of cannabis accessories and lifestyle products across the U.S., Canada, and Europe, operating in Consumer Goods and Industrial Goods segments [6][8]. - Greenlane has announced its strategy to deliver quality and a diverse selection of cannabis products, emphasizing value for customers [9].

Core Points - SNDL Inc. has commenced trading on the Canadian Securities Exchange (CSE) under the symbol "SNDL" effective April 11, 2025, providing the company with additional operational flexibility and opportunities for shareholders to transact in Canadian dollars [1][2] - The CSE listing enhances SNDL's structural flexibility and aligns with its long-term vision, allowing the company to pursue growth opportunities with greater agility [2] - SNDL is one of the largest vertically integrated cannabis companies in Canada and the largest private-sector liquor and cannabis retailer, with a diverse portfolio of retail brands and consumer-facing cannabis products [3]

TAMPA, Fla., April 10, 2025 (GLOBE NEWSWIRE) -- FLUENT Corp. (CSE: FNT.U) (OTCQB: CNTMF) ("FLUENT" or the "Company"), a national cannabis consumer packaged goods company and retailer, today announced it will report financial results for the fourth quarter ended December 31, 2024, on Thursday, April 17, 2025. The Company will host a conference call and live audio webcast to discuss the financial results and provide investors with key business highlights. CONFERENCE CALL DETAILS Event:FLUENT Corp. Fourth Quar ...

Core Viewpoint - A securities class action lawsuit has been filed against Canopy Growth Corporation for failing to disclose significant costs related to product launches, which negatively impacted financial results and gross margins [1][2]. Group 1: Lawsuit Details - The lawsuit is on behalf of all individuals or entities that purchased Canopy securities between May 30, 2024, and February 6, 2025 [1]. - Allegations include failure to disclose significant costs associated with the Claybourne pre-rolled joints and indirect costs from Storz & Bickel vaporizer devices [2]. Group 2: Financial Impact - Canopy announced disappointing financial results on February 7, 2025, attributing them to costs from the Claybourne product launch and increased indirect costs [3]. - Following the announcement, Canopy's share price dropped by 27.24%, closing at $2.02 on the same day [3]. Group 3: Investor Information - Investors who acquired Canopy shares are encouraged to contact the law firm before the lead plaintiff motion deadline of June 3, 2025 [4].

Core Insights - Tilray Brands, Inc. reported revenue of $185.78 million for the quarter ended February 2025, a decrease of 1.4% year-over-year, and an EPS of -$0.10 compared to $0.00 in the same quarter last year [1] - The revenue fell short of the Zacks Consensus Estimate of $209.78 million, resulting in a surprise of -11.44%, while the EPS surprise was -150.00% against a consensus estimate of -$0.04 [1] Revenue Breakdown - Cannabis business revenue was $54.27 million, below the estimated $66.21 million, reflecting a year-over-year decline of 14.4% [4] - Wellness business revenue reached $14.09 million, slightly below the average estimate of $14.35 million, marking a year-over-year increase of 5% [4] - Beverage business revenue was reported at $55.92 million, compared to the estimated $63.20 million, showing a year-over-year growth of 2.3% [4] - Distribution business revenue amounted to $61.49 million, slightly below the average estimate of $61.92 million, with a year-over-year increase of 8.3% [4] Stock Performance - Over the past month, shares of Tilray Brands have returned -11%, compared to a -12.2% change in the Zacks S&P 500 composite [3] - The stock currently holds a Zacks Rank 3 (Hold), indicating potential performance in line with the broader market in the near term [3]

LOS ANGELES, April 8, 2025 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Canopy Growth Corporation ("Canopy Growth" or "the Company") (NASDAQ: CGC) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.Investors who purchased the Company's securities between May 30, 2024 and February 6, 2025, inclusive (the "Class ...

Group 1: Company Overview - Tilray Brands went public in 2018 and has since faced significant challenges, with the stock losing nearly all its value despite the U.S. cannabis market exceeding $38 billion last year [1][2] - The company has evolved into a global cannabis business, initially focusing on medical cannabis and later expanding into recreational cannabis, hemp foods, and beverages [4][5] - Tilray currently sells over 40 brands of cannabis products and generated $829 million in sales last year, with projected revenue growth to $893 million this year and $943 million next year [5][6] Group 2: Financial Performance - While sales are not a concern, Tilray has struggled with profitability, reporting a free cash flow of minus $92 million and net losses nearing $250 million last year [7][8] - The U.S. cannabis market is expected to grow over 11% annually through 2030, presenting opportunities for Tilray's diverse product portfolio [6] Group 3: Challenges and Risks - The company has faced operational challenges due to varying legal statuses of cannabis across states in the U.S., leading to pricing pressures and competition from the black market [8] - Tilray's rapid expansion has resulted in a 348% increase in diluted share count since 2018, which negatively impacts revenue and profit distribution among shareholders [9][10] - Despite potential future growth, the stock is unlikely to yield significant returns for investors due to ongoing losses and share dilution [11]

Core Insights - Standard Wellness Holdings, LLC has successfully closed a $14 million senior secured credit facility with Advanced Flower Capital Inc. to refinance existing debt and fund the acquisition of a dispensary license in Saint Louis, Missouri [1][2]. Financial Overview - The credit facility carries an interest rate of 12.5% and is aimed at streamlining Standard Wellness's debt structure, eliminating legacy obligations, and supporting strategic acquisitions [2][3]. - The financing will fully repay the company's debt facility with Focus Growth Capital Partners and the seller note with Columbia Care [1][3]. Strategic Growth - The acquisition of the dispensary license in Saint Louis is a key component of Standard Wellness's long-term growth strategy, pending regulatory approval [1][3]. - The company aims to expand its footprint in key markets, demonstrating a commitment to strategic expansion and financial discipline [2][3]. Company Background - Standard Wellness, founded in 2017, operates in Ohio, Missouri, and Utah, with cultivation, processing, and dispensary licenses in Maryland [5]. - The company has a workforce of approximately 350 employees and is dedicated to providing safe and legal access to cannabis for medical and adult use [6]. Industry Context - Advanced Flower Capital Inc. is a leading commercial mortgage REIT that provides loans to state-law compliant cannabis operators in the U.S., highlighting the growing financial support for the cannabis industry [7].

Portfolio Highlights - The company has a total portfolio investment value of approximately $275 million[12] - The gross weighted-average yield of the company's debt investments is 165%[12] - 100% of the company's current debt investments are senior secured[12] - Approximately 80% of the debt investments are floating rate loans[16], and almost all of these have floors[16] Financial Performance - Gross investment income for the quarter ended December 31, 2024, was $127 million[24], compared to $36 million for the quarter ended December 31, 2023[24] - Net investment income for the year ended December 31, 2024, was $95 million[24], compared to $66 million for the year ended December 31, 2023[24] - Net assets at the end of the period were $3012 million[24] Market Opportunity - The U S cannabis industry is estimated to be a $32 billion market in top-line retail revenue in 2024[43] and is projected to grow to $58 billion by 2030[43] - Chicago Atlantic estimates it represents approximately 20% of the current U S cannabis debt market, with $23 billion in closed cannabis loans to date[48] Pipeline - The company has an active pipeline under evaluation of approximately $644 million[12] - The active pipeline is comprised of approximately 77% cannabis and 23% non-cannabis opportunities[50]